Pemvidutide (ALT-801)

Published · Researched 2026-09-21

1. Overview

• Maker: Altimmune, Inc. Development code ALT-801.
• Purpose: Dual GLP-1 / glucagon receptor agonist — a balanced (reported ~1:1) dual agonist developed primarily for MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) and obesity. Positioned on liver-fat reduction, lipid lowering, and lean-mass preservation rather than maximal appetite suppression. Notable: designed to need no dose titration.
• Current 2026 version: Investigational — Phase 2 complete (MOMENTUM obesity; IMPACT Phase 2b MASH with 48-week data); PERFORMA Phase 3 MASH registrational trial began enrolling August 3, 2026 (52-week readout anticipated 2029). Also in development for alcohol use disorder and alcohol-associated liver disease. Not approved or marketed anywhere.

2. Social standing

• Platform pulse: Thin. Pemvidutide is a pipeline-watchers' drug, not a users' drug — almost all discussion is about trial data, receptor affinities, and the stock, not personal experience. No owner/user experience reports found.
• Facebook group consensus: No hits in the Facebook groups searched via facebook-cli (Sept 2026).
• Viral moments: None observed.
• Praise: glp1forum thread "Newcomer Pemvidutide" — members cite "best results in phase 3 clinical trials for liver fat reduction and a massive reduction of blood cholesterol/lipids" (note: actually Phase 2 — corrected by another member in-thread), lean-mass preservation, and one detailed poster arguing its glucagon affinity makes it the pick for lipid/triglyceride concerns over sema/tirz/reta. One member organized a custom group-buy batch ("I found a supplier who is willing to make a batch of Pemvidutide for us... Anyone interested?") with others expressing interest.
• Complaints: Skepticism dominates: members debate whether receptor-affinity charts mean anything for real efficacy ("The gold standard for efficacy is a randomised controlled trial. Not lab reports"); weak A1c effect noted as a limitation for diabetic patients (per a Jefferies expert-call transcript: "you can't give a drug to patients with diabetes that raise your blood glucose... a nogo"); Altimmune's stock history draws mockery ("This is the weirdest company to me").
• Verified quotes (paraphrased, attributed):
  • glp1forum member: "A new drug currently being tested which is called Pemvidutide (a dual receptor agonist of Glp1/Glucagon) has a stronger affinity towards glucagon compared to reta... if it is blood lipids/triglycerides/cholesterol that is your main concern... a drug with higher affinity towards Glucagon is needed." — platform: glp1forum.com "Newcomer Pemvidutide" thread.
  • glp1forum member: "It has a very minimal effect on A1c, but not intended for glucose reduction. Intended for blood cholesterol and lipids reduction. At that it does a wonderful job of approx 70% reduction of fatty liver." — platform: glp1forum.com.
  • Threads user @drivenonesllc: listed "CagriSema, MariTide, Survodutide, Pemvidutide, Orforglipron, and Eloralintide" as the diverse next-generation pipeline — platform: Threads.
  • Threads user @docfathealth (Chinese-language post): discussed Altimmune facing a market test on its pemvidutide fatty-liver drug similar to Amgen's MariTide Phase 2 reaction — platform: Threads.
  • Jefferies expert call (Dr. Apovian): "The lack of a titration is big... Then the benefits, if it really does have extra liver effects beyond the weight loss, then yes, then it will be a benefit." — via javatar.bluematrix.com transcript.

3. Social validation — Tier 3 (weak)

• Tier 3 — flagged as weak. One genuine community forum thread plus two Threads pipeline-watch mentions; no Facebook Groups presence, no IG owner content, and critically no firsthand user experience reports anywhere found.
• Named sources and what each proves:
  1. glp1forum.com "Newcomer Pemvidutide" thread (~29 posts, incl. Dec 2024 group-buy organizing) — proves real community interest and purchase intent, but discussion is theoretical/comparative, not experiential.
  2. Threads posts by @drivenonesllc and @docfathealth — proves pipeline-watch awareness among health-investor commentators; not user experience.
  3. Searched but empty: Facebook group post queries (Sept 2026), Reddit discussion threads, Instagram owner content.

4. Key specs table

5. Pricing (dated 2026-09-20)

• Current MSRP (brand): None — investigational, no approved product or price.
• Street price (research/compounded): Not observed — a Dec 2024 glp1forum group-buy effort never posted a firm price; no retail vendor listing with price found in Sept 2026 searches. UNVERIFIED.
• Marketplace used range: None observed.

6. What is included / what else is needed

• Brand: N/A (no product).
• Gray-market (if ever sourced): Would be lyophilized powder vial — bacteriostatic water, insulin syringes, alcohol swabs required. Research chemical not for human use.

7. Support reality

• Brand: N/A.
• Gray-market: No warranty/returns; the only sourcing trace is a forum group-buy that may never have materialized. Assume no recourse.

8. Community verdict

Pemvidutide is the peptide world's "interesting on paper" candidate: respected for best-in-class liver-fat and lipid data with unusually clean tolerability, but the community conversation is almost entirely theoretical — affinity charts, trial readouts, and stock-chart jokes. With no firsthand user reports and no confirmed gray-market supply, it remains a pipeline name to watch rather than a compound the community actually uses.

9. Regulatory & safety status

• Investigational drug — NOT FDA/EMA approved. Altimmune's pemvidutide is in Phase 2→3 transition for MASH/obesity. Any vial sold online would be an unapproved research chemical not for human use.
• Known safety signals: Phase 2b showed low discontinuation due to AEs (0–1.2% vs 3.5% placebo); no drug-related SAEs or arrhythmias reported at 24 weeks; GI tolerability described as favorable with no titration. Minimal HbA1c effect — a limitation for diabetic populations, not a safety signal per se.

10. Missing-image views + UNVERIFIED points log

• Images found (0/8): No verified pemvidutide product photos exist publicly — no brand product, no confirmed vendor listings with photography. All views missing: hero, side, rear, top, detail, owner-in-use, scale, box/accessories. (Generic peptide-vial stock images were found but rejected as untraceable/misleading.)
• UNVERIFIED:
  1. Exact half-life and molecular details.
  2. FDA fast-track designation for MASH — community-claimed, not confirmed in fetched sources.
  3. RESOLVED: "balanced 1:1" GLP-1/glucagon ratio — confirmed by Altimmune company materials (Aug 2026 PERFORMA announcement: "balanced glucagon/GLP-1 dual receptor agonist"; ainvest.com, Sept 2026).
  4. ~70% fatty-liver reduction figure — forum member claim, not matched to a fetched primary source.
  5. Any street price — none observed.
  6. Community receptor-affinity comparisons — user-compiled charts, not primary data.
  7. FDA fast-track designation for MASH — community-claimed, not confirmed in fetched sources.

Not medical advice. This is research material only; consult a qualified clinician.

Named sources

• glp1forum.com "Newcomer Pemvidutide" thread (~29 posts, incl. Dec 2024 group-buy organizing) — proves real community interest and purchase intent, but discussion is theoretical/comparative, not experiential. (Dec 2024)
• Threads posts by @drivenonesllc and @docfathealth — proves pipeline-watch awareness among health-investor commentators
• Altimmune releases — Mechanism: Dual GLP-1R/GCGR agonist, reported balanced ~1:1 ratio; glucagon activity inhibits PCSK9 → lowers lipids; minimal glycemic effect by design
• Altimmune IMPACT/MOMENTUM releases — Dosing schedule: Weekly subcutaneous; trial doses 1.2 mg and 1.8 mg; no titration required (key differentiator)
• Jefferies expert call — Dosing schedule: Weekly subcutaneous; trial doses 1.2 mg and 1.8 mg; no titration required (key differentiator)
• Trial design — Administration route: Subcutaneous injection (investigational)
• GlobeNewswire via hattiesburg.com — Trial phase: Phase 3 enrolling: PERFORMA (global registrational MASH trial in F2–F3 fibrosis patients), enrollment began Aug 3, 2026; 52-week readout anticipated 2029. (Aug 3, 2026)
• marketbeat.com FDA-events tracker — Trial phase: Phase 3 enrolling: PERFORMA (global registrational MASH trial in F2–F3 fibrosis patients), enrollment began Aug 3, 2026; 52-week readout anticipated 2029. (Aug 3, 2026)
• globenewswire.com — Measured efficacy: MOMENTUM (24 wks, obesity): 7.3% / 9.4% / 10.7% at 1.2/1.8/2.4 mg vs 1.0% placebo.
• quiverquant.com — Measured efficacy: MOMENTUM (24 wks, obesity): 7.3% / 9.4% / 10.7% at 1.2/1.8/2.4 mg vs 1.0% placebo.
• barchart.com — Measured efficacy: MOMENTUM (24 wks, obesity): 7.3% / 9.4% / 10.7% at 1.2/1.8/2.4 mg vs 1.0% placebo.
• javatar.bluematrix.com — Then the benefits, if it really does have extra liver effects beyond the weight loss, then yes, then it will be a benefit." — via javatar.bluematrix.com transcript.

Source URLs were not recorded for these references.